NCT06220604

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Name: Clinical Trial NCT06220604
Creator: Janssen Research & Development, LLC
Keywords: Plaque Psoriasis, JNJ-77242113, Phase 3, drug, clinical trial, Australia,South Korea,Taiwan

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Janssen Research & Development, LLC·Phase 3·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Plaque Psoriasis
Drug/Device/Intervention: JNJ-77242113
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Janssen Research & Development, LLC
Location: Mitcham,Ansan-si,Anyang-si,Gwangju,Tainan, Australia,South Korea,Taiwan

Timeline & enrollment

Phase: Phase 3
Start date: Mar 09, 2024
End date: Sep 20, 2027
Enrollment: 675 participants

Primary outcome

JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (=) 2 Grade Improvement From Baseline at Week 16,JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

Summary

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

ICD-10 classifications

PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06220604
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06220604 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen Research & Development, LLC and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 675 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.